📢 Brazil and Thailand become the first malaria-endemic countries to launch new single-dose relapse prevention medicine for Plasmodium vivax (P. vivax) malaria P. vivax is the dominant malaria parasite in many countries outside of sub-Saharan Africa and is characterised by clinical relapses. Without treatment for the latent liver-stage infection, patients experience repeated bouts of illness, imposing significant physical, economic, and social burdens on both individuals and communities. Relapses also increase the disease burden and the potential for onward transmission, ultimately impeding global efforts to eliminate malaria. Developed through a longstanding partnership Medicines for Malaria Venture, tafenoquine, co-administered with chloroquine, offers a new potential treatment option for vulnerable populations who are disproportionately affected by this disease. By continuing to invest in global health R&D, strengthening healthcare systems, and enabling access to healthcare in lower-income countries, together with our partners we can help change the trajectory of malaria. #ChangeTheTrajectory #Malaria #GlobalHealth #ZeroMalaria
About us
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
- Website
-
http://www.gsk.com
External link for GSK
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Brentford, Middlesex
- Type
- Public Company
- Specialties
- Pharmaceutical products and Vaccines
Locations
Employees at GSK
Updates
-
#News for #investors and #media: Today we announced a new licensing agreement with CureVac. This is our latest investment in vaccine platform technologies, allowing us to match the best platform to each pathogen and help prevent illness in more people around the world. Read more: https://gsk.to/4eOUVoJ
-
We’re highlighting the importance of early action to help prevent irreversible organ damage in people with lupus. Global experts are recognising the extensive data to support the timely use of evidence-based treatments to help reduce the risk of permanent kidney damage. Learn more at our dedicated GSK site: https://gsk.to/3L15zew
-
Today, we’ve signed a new 10-year energy deal in Singapore with Sembcorp which is set to increase our global purchased renewable electricity usage by 9% from 2025. With this new agreement, all three of our medicines and vaccines manufacturing sites in Singapore will be covered by 100% renewable electricity generated directly at the site and purchased through renewable energy certificates from solar projects. Our sites in Singapore are critical for the production of innovative medicines and vaccines for HIV, oncology and infectious diseases. We know that climate change is already having a negative impact on human health, and we are committed to playing our part in protecting the health of both people and the planet to help get ahead of disease together. #LCAW2024
-
"Can we end epidemics?" is a brand new 6-episode podcast series from ViiV Healthcare, in partnership with Foreign Policy. Episode 5, ‘Reaching New Heights,’ brings together GSK’s Fiona Smith-Laittan and AMREF’s Dr Mercy Mwangangi to discuss: 🌍 What it takes to deliver health impact at scale? 💡 Why must global health innovation be accelerated? 🤝 And how can partnerships help build, strengthen and future-proof health systems? Take a listen wherever you get your podcasts! Or find out more, here: https://gsk.to/3RHnk6s
-
Healthy people need a healthy planet. That’s why we’re using science, technology and talent to help deliver our ambitious sustainability goals. By including climate and nature considerations in product discovery and development, GSK people are working together to design our medicines and vaccines to be more sustainable from the start. Meet Zack, an inspired GSK chemist, early riser and planet protector, working on green chemistry solutions to minimise waste, reduce our energy use and improve productivity. Through cutting-edge research, Zack and his team are working to develop more sustainable medicines and vaccines to benefit patients and the planet. Learn more at https://lnkd.in/dvmG8r75 and explore career opportunities at https://lnkd.in/eztbEUd. #GSKCareers #WeAreGSK #LCAW2024
-
This London Climate Action Week we’re focused on how we’re working across our business, and together with our suppliers and partners, to develop more sustainable medicines and vaccines. We’re harnessing the very best of GSK’s science, technology and talent, from using our scientific expertise to help to make our new products sustainable by design, to transitioning to renewable energy to power our manufacturing sites. Stay tuned for updates throughout the week and learn more about the work we’re already doing to support healthcare systems that are better for patients and better for the planet. https://gsk.to/4eCmqly #LCAW2024
-
-
#News for #Investors and #Media: Today, we announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted approval for our blood cancer therapy. Learn more: https://gsk.to/3VT5pMC
-
#News for #Investors and #Media: Today, we announced that our marketing authorisation application for a potential expanded indication for our immuno-oncology therapy has been validated by the European Medicines Agency (EMA). Learn more: https://gsk.to/4carMTi